A5080463002- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Pharmacology and Obesity Treatment
- Chronic Kidney Disease and Diabetes
- Diet and metabolism studies
- Gastric Cancer Management and Outcomes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Education
- Muscle metabolism and nutrition
- Cardiovascular and exercise physiology
- Genetic Associations and Epidemiology
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Skin Diseases and Diabetes
- Renal Diseases and Glomerulopathies
- Renin-Angiotensin System Studies
- Chronic Disease Management Strategies
- Heart Rate Variability and Autonomic Control
- Genetic Syndromes and Imprinting
Swansea University
2016-2025
Swansea Bay University Health Board
2015-2025
Singleton Hospital
2013-2024
Monmouthshire County Council
2023
The University of Texas Southwestern Medical Center
2023
University of Wales
2005-2023
Novo Nordisk (Denmark)
2018-2023
Collegio Carlo Alberto
2023
Chr. Hansen (Denmark)
2023
Slagelse Hospital
2021
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available the subcutaneous form glucagon-like peptide-1 receptor agonist semaglutide but needed oral semaglutide.
Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes.In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects diabetes early nephropathy to receive either blocker telmisartan (80 mg daily, 120 subjects) or ACE inhibitor enalapril (20 130 subjects). The primary end point was change glomerular filtration rate (determined by...
The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy safety of varying daily injection degludec (IDeg), an ultra-long-acting insulin.This 26-week, open-label, treat-to-target enrolled adults (≥18 years) with type 2 diabetes who were either naïve receiving oral antidiabetic drugs (OADs) (HbA(1c) = 7-11%) or previously on ± OAD(s) 7-10%). Participants randomized 1) once-daily...
OBJECTIVE This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA1c 7.5–10.5%). RESEARCH DESIGN AND METHODS Patients were randomized 1:1:1 5 mg (n = 271), 10 270), or placebo 272) plus insulin. Insulin dose was adjusted by investigators according self-monitored glucose readings, local guidance,...
To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme.The programme evaluated efficacy and safety of semaglutide, a glucagon-like peptide-1 analogue, for treatment type 2 diabetes (T2D). In 6, 2-year, pre-approval cardiovascular outcomes trial, semaglutide was associated with significant increase in risk DR complications (DRC) vs placebo. trials were evaluated, post hoc analyses 6 conducted. These included subgroup to identify at-risk patients mediation...
This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying injection timing day to in subjects with type 1 diabetes. 26-week, open-label, treat-to-target, noninferiority trial compared IDeg forced flexible (Forced-Flex) OD (given a fixed schedule minimum 8 maximum 40 hours between doses) or glargine (IGlar) given at same time OD. In 26-week extension, all were transferred free-flexible (Free-Flex) regimen, which allowed any-time-of-day dosing,...
OBJECTIVE Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on existing medications patients with inadequately controlled moderate renal impairment. RESEARCH DESIGN AND METHODS In this 26-week, double-blind trial, 279 HbA1c 7–10%, BMI 20–45 kg/m2, (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) once-daily 1.8 mg (n = 140)...
We assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.
Abstract Aim To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: [CV] death, nonfatal myocardial infarction [MI] and stroke) hospitalization for heart failure (HF) in SUSTAIN (subcutaneous semaglutide) PIONEER (oral trials across subgroups varying CV risk. Methods Post hoc analyses individual patient‐level data combined from 6 were performed to assess MACE HF. analysed subjects with without: established disease and/or chronic kidney...
Insulin icodec is an investigational once-weekly basal insulin analogue for diabetes management.We conducted a 78-week randomized, open-label, treat-to-target phase 3a trial (including 52-week main and 26-week extension phase, plus 5-week follow-up period) involving adults with type 2 (glycated hemoglobin level, 7 to 11%) who had not previously received insulin. Participants were randomly assigned in 1:1 ratio receive or once-daily glargine U100. The primary end point was the change glycated...
Glucagon-like peptide-1 receptor agonists reduce albuminuria and may stabilize the estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post hoc analysis of SUSTAIN 6/PIONEER 6 trials encompassing 6480 participants at high cardiovascular risk (semaglutide, 3239 participants; placebo, 3241 participants), we investigated effects semaglutide versus placebo on eGFR decline. Pooled data by treatment were evaluated for annual change (total slope ml/min per 1.73...
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high risk. An assessment the efficacy semaglutide atherosclerotic disease, chronic kidney or both is needed. In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years age older, had glycated hemoglobin level 6.5 to 10.0%, known receive either once-daily (maximal dose, 14 mg)...